After AstraZeneca mRNA deal, CanSino eyes other production partnerships

CanSino Biologics' recent mRNA manufacturing tie-up with AstraZeneca represents just the tip of the iceberg, the company’s CEO has said.

After jumping into the mRNA game back in 2018, CanSino has built a facility in Shanghai that can produce up to 200 million vaccine doses a year, the company’s co-founder and CEO Xuefeng Yu told Reuters in a recent interview.